Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database (Q34422144)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database |
scientific article |
Statements
1 reference
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database (English)
1 reference
Byron J Hoogwerf
1 reference
Jennie H Best
1 reference
William H Herman
1 reference
Elise M Pelletier
1 reference
Daniel B Smith
1 reference
Made Wenten
1 reference
Mohamed A Hussein
1 reference
7 October 2010
1 reference
1 reference
1 reference
Identifiers
1 reference